| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Deltarasin HCl targets the interaction between KRAS and PDEdelta, a chaperone protein that facilitates proper KRAS membrane localization. PDEdelta binds to farnesylated KRAS and transports it to the plasma membrane. By inhibiting this interaction with a Kd of 38 nM, Deltarasin HCl prevents proper KRAS membrane localization and downstream signaling. This makes PDEdelta a therapeutic target.
|
||
|---|---|---|---|
| ln Vitro |
Deltarasin inhibits the interaction between RAS and PDEδ in liver cells, with a KD of 41 nM. When deltarasin inhibits the PDEδ-KRAS connection, human pancreatic ductal adenocarcinoma cells that rely on oncogenic KRAS proliferate less[1].
Deltarasin HCl demonstrates potent in vitro inhibition of KRAS-PDEdelta interaction with a Kd of 38 nM for binding to purified PDEdelta. The compound shows high affinity for PDEdelta and effectively disrupts KRAS-PDEdelta binding. In liver cells, the compound demonstrates biological activity. Deltarasin HCl is used as a research tool to study KRAS biology and signaling. |
||
| ln Vivo |
When human Panc-Tu-I tumor cell xenografts are subcutaneously placed in nude mice, deltarasin (10 mg/kg, ip) reduces the tumor's growth in a dose-dependent manner[1].
In vivo data for Deltarasin HCl is primarily focused on its use as a research tool for studying KRAS-PDEdelta interactions. The compound has been studied for its potential to inhibit KRAS signaling in cellular and potentially animal models. As an inhibitor of KRAS membrane localization, it may have implications for KRAS-driven cancers. However, the compound is not clinically approved. |
||
| Enzyme Assay |
In vitro binding assays for Deltarasin HCl typically employ purified PDEdelta protein and measure binding affinity using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization. The Kd of 38 nM is determined from binding isotherms. Competition assays with labeled KRAS or fluorescent probes assess inhibition of KRAS-PDEdelta interaction. Assays are performed in appropriate buffers at physiological pH and temperature.
|
||
| Cell Assay |
Cellular assays for Deltarasin HCl involve treating KRAS-mutant cancer cell lines with varying concentrations of the compound (typically 0.001-10 microM range) for 24-72 hours. Readouts include assessment of KRAS membrane localization by immunofluorescence or cell fractionation, downstream signaling pathway activity (e.g., ERK, AKT phosphorylation) by Western blotting, and cell viability. PDEdelta binding and inhibition of KRAS localization are confirmed.
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Deltarasin HCl are characteristic of small molecule inhibitors. The compound is soluble in DMSO (≥52 mg/mL). Following administration, PK parameters including half-life, Cmax, Tmax, and AUC are determined via LC-MS/MS analysis. The hydrochloride salt form provides favorable solubility. Bioavailability depends on formulation and route of administration. The compound is typically stored at 2-8degC.
|
||
| Toxicity/Toxicokinetics |
Deltarasin HCl is a research compound with limited publicly available toxicology data. As with all research chemicals, standard safety precautions should be observed during handling including appropriate PPE and work in a fume hood. The compound is not clinically approved. Comprehensive toxicology studies would be required for clinical development. The compound is for research use only.
|
||
| References | |||
| Additional Infomation |
Deltarasin HCl (CAS# 1613404-76-4) is a potent inhibitor of KRAS-PDEdelta interaction. It is also known as deltarasin hydrochloride. The compound is primarily used as a research tool to study KRAS biology and signaling. PDEdelta is a chaperone protein essential for proper KRAS membrane localization. The compound is not clinically approved. It is typically stored at 2-8degC, dry and sealed.
|
| Molecular Formula |
C40H38CLN5O
|
|---|---|
| Molecular Weight |
640.215628147125
|
| Exact Mass |
639.276
|
| CAS # |
1613404-76-4
|
| Related CAS # |
Deltarasin;1440898-61-2;Deltarasin trihydrochloride;1440898-82-7
|
| PubChem CID |
78357804
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
47
|
| Complexity |
923
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CNCCC1[C@@H](COC2=CC=C(C=C2)C3=NC4=CC=CC=C4N3CC5=CC=CC=C5)N6C7=CC=CC=C7N=C6C8=CC=CC=C8.Cl
|
| InChi Key |
RNNBDBVWCNENOV-XVYLPRMCSA-N
|
| InChi Code |
InChI=1S/C40H37N5O.ClH/c1-3-11-29(12-4-1)27-44-36-17-9-7-15-34(36)42-39(44)32-19-21-33(22-20-32)46-28-38(30-23-25-41-26-24-30)45-37-18-10-8-16-35(37)43-40(45)31-13-5-2-6-14-31;/h1-22,30,38,41H,23-28H2;1H/t38-;/m1./s1
|
| Chemical Name |
1-benzyl-2-[4-[(2S)-2-(2-phenylbenzimidazol-1-yl)-2-piperidin-4-ylethoxy]phenyl]benzimidazole;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 52 mg/mL (~81.22 mM)
H2O : ~50 mg/mL (~78.10 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5620 mL | 7.8098 mL | 15.6196 mL | |
| 5 mM | 0.3124 mL | 1.5620 mL | 3.1239 mL | |
| 10 mM | 0.1562 mL | 0.7810 mL | 1.5620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
